Go online to PeerView.com/UHK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early detection and diagnosis of Alzheimer’s disease (AD) can give patients more control over their health and future and can lead to improved outcomes. Significant advances have been made in the development of neuroimaging biomarkers, including amyloid PET and tau PET, that may aid in the early diagnosis of AD, facilitate patient selection for treatment, and monitor therapeutic response. With the anticipated growth in patients with AD around the globe and evolving developments in AD assessment and treatment, radiologists and nuclear medicine physicians are poised to play an increasingly vital role throughout AD management. In this activity, based on a recent live symposium, a panel of expert faculty discusses the importance of a timely and accurate diagnosis of AD, as well as recent research related to the evolving and complementary role of neuroimaging and fluid biomarkers in the early diagnosis and ongoing management of AD. Upon completion of this activity, participants should be better able to: Recognize the importance of making a timely and accurate neuropathological diagnosis of AD; Apply current and emerging diagnostic tools to optimize the neuropathological diagnosis of AD early in the disease course; and Identify the advantages and limitations associated with PET, cerebrospinal fluid (CSF), and plasma biomarkers
View all episodes
